A clinical study of CBP-4888, in pregnant preeclamptic patients
Latest Information Update: 22 Jan 2024
At a glance
- Drugs CBP-4888 (Primary)
- Indications Preeclampsia
- Focus Adverse reactions
- 22 Jan 2024 New trial record
- 17 Jan 2024 According to a Comanche Biopharma media release, the proceeds from an oversubscribed $75 million Series B financing will be used to initiate this trial. The company plans to initiate this trial later this year.